Pfizer Inc. (NYSE:PFE) Q3 2018 Earnings Call October 30, 2018 10:00 AM ET
Executives
Charles E. Triano - Pfizer Inc.
Ian C. Read - Pfizer Inc.
Albert Bourla - Pfizer Inc.
Frank A. D'Amelio - Pfizer Inc.
John D. Young - Pfizer Inc.
Angela Hwang - Pfizer Inc.
Mikael Dolsten - Pfizer Inc.
Analysts
Alex Arfaei - BMO Capital Markets (United States)
Vamil K. Divan - Credit Suisse Securities (NYSE:USA) LLC
Chris Schott - JPMorgan Securities LLC
Jami Rubin - Goldman Sachs & Co. LLC
John T. Boris - SunTrust Robinson Humphrey, Inc.
Steve Scala - Cowen & Co. LLC
Umer Raffat - Evercore Group LLC
Louise Chen - Cantor Fitzgerald Securities
David R. Risinger - Morgan Stanley & Co. LLC
Geoff Meacham - Barclays Capital, Inc.
Timothy Minton Anderson - Wolfe Research, LLC
Andrew S. Baum - Citigroup Global Markets Ltd.
Jason M. Gerberry - Bank of America Merrill Lynch
Operator
Good day, everyone, and welcome to Pfizer's Third Quarter 2018 Earnings Conference Call. Today's call is being recorded.
At this time, I would like to turn the call over to Mr. Chuck Triano, Senior Vice President of Investor Relations. Please go ahead, sir.
Charles E. Triano - Pfizer Inc.
Good morning and thank you for joining us today to review Pfizer's third quarter 2018 performance. I'm joined today by our Chairman and CEO, Ian Read; Albert Bourla, our Chief Operating Officer; Frank D'Amelio, our CFO; Mikael Dolsten, President of Worldwide Research and Development; Angela Hwang, Group President, Pfizer Essential Health; John Young, Group President, Pfizer Innovative Health; and Doug Lankler, our General Counsel.
The slides that will be presented on this call can be viewed on our website, pfizer.com/investors. Before we start, I'd like to remind you that our discussion during this call will include forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those projected in the forward-looking statements.
